FY2025 Earnings Forecast for BMY Issued By Cantor Fitzgerald

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Bristol Myers Squibb in a research report issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings per share of $6.28 for the year, down from their previous forecast of $6.89. Cantor Fitzgerald currently has a "Neutral" rating and a $55.00 price target on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same period last year, the business posted ($4.40) earnings per share. Bristol Myers Squibb's quarterly revenue was down 5.6% compared to the same quarter last year.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group decreased their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Morgan Stanley decreased their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a report on Thursday. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Finally, Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Bristol Myers Squibb has an average rating of "Hold" and a consensus target price of $57.69.

Bristol Myers Squibb Stock Down 3.3%

BMY traded down $1.61 on Friday, hitting $46.91. The company had a trading volume of 13,670,701 shares, compared to its average volume of 12,845,758. The stock has a fifty day simple moving average of $47.51 and a 200-day simple moving average of $53.28. Bristol Myers Squibb has a 52-week low of $39.93 and a 52-week high of $63.33. The firm has a market capitalization of $95.47 billion, a P/E ratio of 17.57, a P/E/G ratio of 2.43 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.09% of the company's stock.

Institutional Trading of Bristol Myers Squibb

Several hedge funds have recently bought and sold shares of BMY. Pinney & Scofield Inc. purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb during the 4th quarter valued at about $26,000. Global Wealth Strategies & Associates grew its holdings in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. Transce3nd LLC bought a new position in Bristol Myers Squibb in the 4th quarter worth about $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol Myers Squibb in the 1st quarter worth about $31,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.